Accuracy of the new rapid test for monitoring adalimumab levels

Publication

dc.contributor.author	Rocha, C
dc.contributor.author	Afonso, J
dc.contributor.author	Lago, P
dc.contributor.author	Arroja, B
dc.contributor.author	Vieira, AI
dc.contributor.author	Dias, CC
dc.contributor.author	Magro, F
dc.date.accessioned	2019-05-16T12:44:42Z
dc.date.available	2019-05-16T12:44:42Z
dc.date.issued	2019
dc.description.abstract	The loss of response to adalimumab (ADL) has been related to low serum concentrations at trough. Currently, most methods commercially available for the quantification of ADL are enzyme-linked immunosorbent assay (ELISA) based, with a turnaround time of approximately 8 h, delaying the target dosage adjustment to the subsequent infusion. In this study, we aimed to evaluate the performance of the newly available rapid-test ADL quantification assay by comparing it with three established ELISA methods, using spiked samples and a set of clinical samples.	pt_PT
dc.description.version	info:eu-repo/semantics/publishedVersion	pt_PT
dc.identifier.citation	Therap Adv Gastroenterol. 2019 Feb 27;12:1756284819828238.	pt_PT
dc.identifier.doi	10.1177/1756284819828238	pt_PT
dc.identifier.uri	http://hdl.handle.net/10400.23/1323
dc.language.iso	eng	pt_PT
dc.peerreviewed	yes	pt_PT
dc.subject	Adalimumab	pt_PT
dc.title	Accuracy of the new rapid test for monitoring adalimumab levels	pt_PT
dc.type	journal article
dspace.entity.type	Publication
oaire.citation.startPage	1756284819828238	pt_PT
oaire.citation.volume	12	pt_PT
rcaap.rights	openAccess	pt_PT
rcaap.type	article	pt_PT

Files

Now showing 1 - 1 of 1

Now showing 1 - 1 of 1